Primary malignant melanoma of the esophagus treated by endoscopic submucosal dissection: A case report

MEI WANG, JIANPING CHEN, KEWEN SUN, YUN ZHUANG, FU XU, BIN XU, HONGYU ZHANG, QING LI and DACUAN ZHANG

Departments of Digestion, Tumor Biological Treatment, Oncology and Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China

Received February 8, 2015; Accepted May 18, 2016

DOI: 10.3892/etm.2016.3482

Abstract. Primary malignant melanoma of the esophagus (PMME) is a rare malignant neoplasm of the esophagus. In the majority of cases, the disease originates in the mucosal layer of the esophagus, which is similar to other types of esophageal cancer. With the development of endoscopic submucosal dissection (ESD), endoscopic resection is possible for cases in which melanomas are limited to the mucosal and submucosal layer. However, few studies report the efficiency of ESD for PMME, and no studies perform long-term follow-up. The present study reported the case of a 71-year-old PMME patient who was successfully treated by ESD at the Third Affiliated Hospital of Soochow University (Changzhou, China) in October 2011, with a follow-up of >3 years conducted.

Introduction

Primary malignant melanoma of the esophagus (PMME) has only ~300 cases reported in the literature (1,2). It is a rare malignant disease, accounting for 0.1-0.2% of esophageal malignancies. Definitive diagnoses depend on pathology and immunohistochemical examination with positive results for S-100, human melanoma black (HMB)-45 and melanoma-specific antigen (Melan-A) proteins. PMME has a 5-year survival rate of 2.2-4.2% and the present standard treatment is surgical resection (3). In recent years, few cases of PMME patients undergoing endoscopic mucosal resection (EMR) have been reported. At present, endoscopic submucosal dissection (ESD) is used to treat tumors originating from the mucosal or submucosal layer due to the possibility of en bloc resection of lesions regardless of their size and shape (4). Theoretically, due to the similarity of the site of origin of PMME compared with other operable tumors, ESD may be a viable option for its treatment. However, to the best of our knowledge, no case of PMME treated with ESD has been reported, and the follow-up requirements and complications of PMME subsequent to endoscopic treatment remain unexplored.

The present study reports the case of a 71-year-old PMME patient who was treated by ESD at the Third Affiliated Hospital of Soochow University (Changzhou, China) in 2011. In addition, a follow-up period of >3 years was conducted.

Case report

A 71-year-old female patient was admitted to the Third Affiliated Hospital of Soochow University with complaints of progressive dysphagia in December 2011. The patient had been diagnosed with breast carcinoma and had undergone radical surgery >2 years earlier. Physical examination was normal and revealed no skin lesions. Esophagogastroduodenoscopy indicated no metastasis to the lymph nodes, mediastinum or the lungs. Further examinations also ruled out distant metastasis. Additionally, the patient declined surgery for the PMME, and was thus treated with ESD (Fig. 2), subsequent to providing informed consent.

Prior to the procedure, the patient received conscious sedation [using midazolam (Jiuxu Pharmaceutical Co., Ltd., Zhejiang, China) or propofol (Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany)] in the left lateral position. Following the submucosal injection, the overlying mucosa was dissected circumferentially. Then, the mass was resected. The primary techniques included the use of a standard therapeutic endoscope (GIF-Q260; Olympus Corporation, Tokyo, Japan),
insulated-tip knife (KD-640L; Olympus Corporation) and a hook-knife (KD-620UR; Olympus Corporation). Subsequent to fasting for 3 days after surgery, the patient was allowed to eat. The post-operative white blood cell count was normal and the patient did not complain of discomfort. Pigmented cellular tumor was stained with hematoxylin and eosin, and positive HMB-45 (A-AH10203; Abgent, San Diego, CA, USA) in immunohistochemical examination confirmed the diagnosis of a PMME (Fig. 3). Following ESD, the patient received three cycles of immunotherapy. Ipilimumab was used as the immunotherapy
for 3 cycles, which is a monoclonal antibody that blocks the checkpoint of cytotoxic T-lymphocyte-associated protein 4 (180 mg per 3 weeks). Follow-up esophagastroduodenoscopy examinations and CT scans showed no signs of disease recurrence for >3 years. The latest clinical follow-up was in January 2016, and the esophagastroduodenoscopy examinations and CT scans showed no signs of disease recurrence. The patient has had a normal life for >4.5 years.

Discussion

PMME is an aggressive and fatal disease associated with poor prognosis, and the incidence of PMME accounts for 0.1-0.2% of esophageal malignancies (5). It typically occurs within the lower two-thirds of the esophagus due to the presence of a high concentration of melanin pigment. The etiology and natural course of the disease remains unknown; however, several studies have hypothesized that esophageal melanocytosis may be a precursor to PMME (6,7). This melanoma tends to metastasize readily via the hematogenous and lymphogenous routes. The most common sites of metastases are the liver, mediastinum, mediastinal lymph nodes, the lungs, and the brain (8). The symptoms of PMME are not unique compared with other types of esophageal malignancies. The most common complaint include dysphagia and retrosternal pain. HMB-45, AE1/AE3 and S-100 cytoplasmic proteins are the monoclonal antibodies most frequently used to identify PMME (2,3).

Recently, EUS has been employed to identify the depth of invasion and the node status in patients diagnosed with PMME (9). On EUS, PMME appears as a hypoechoic mass or with mixed echogenicity compared with the surrounding healthy tissue (9). It has previously been reported that endoscopic ultrasound guided fine-needle aspiration may be used to diagnose PMME (10). The proposed criteria for the diagnosis of PMME are the following: i) The mass possesses the characteristic structure of a melanoma, containing melanin; ii) the adjacent epithelium contains melanocytes; iii) the mass arises from the area of junctional changes in the squamous epithelium; and iv) metastasis of malignant melanoma from other parts of the body is excluded (11).

There is currently no gold standard for the treatment of PMME. Furthermore, it has been reported that 30-40% of patients with PMME present nodal or distant metastases at diagnosis, and ~85% will succumb as a result of distant metastasis regardless of the treatment (2). It is agreed that treatment should be adjusted individually according to the tumor size, location, presence of metastases, patient age and comorbidities observed. However, surgical resection should be considered as the first line treatment for all patients with PMME, since radical surgical extirpation increases the chances of long-term survival (12).

For patients that decline or are unable to undergo radical surgery, palliative treatment is an alternative method and includes radiotherapy, chemotherapy and immunotherapy. However, the aforementioned therapies are not successful in the treatment of PMME, and the mean survival time has been reported to be 13.4 months (10). In recent years, novel therapeutic agents have been approved for the treatment of melanoma; however, few randomized clinical trial studies have supported their efficacy (13). Thus, the resection of the tumor remains the only viable treatment with the potential to cure patients with PMME.

In the present study, the patient had a history of breast carcinoma and had previously undergone surgery 2 years prior to presenting with dysphagia. Subsequent to excluding breast metastasis, the tumor was diagnosed as PMME. As the patient declined radical surgery, ESD was performed, followed by three cycles of immunotherapy. Follow-up examinations with endoscopy and CT revealed that ESD had successfully removed the tumor the entire tumor.

To the best of our knowledge, only a limited number of reports have described the use of endoscopic treatment for PMME (14-16). Kastl et al previously described the implantation of a metal stent to alleviate PMME symptoms, which improved the quality of life in the patient (17). Local endoscopic laser ablation may also serve a role in the palliation of locally advanced tumors that are unresectable (18,19). Furthermore, Miyatani et al reported a case involving a slow growing flat-type PMME that was successfully treated by cap-assisted EMR, with no evidence of recurrence during the 20-month follow-up (15). Compared with EMR, the ESD technique enables the en bloc resection of lesions regardless of their size and shape. In 2013, Eleftheriadiis et al reported a unique case of PMME undergoing successful treatment with ESD and described an uneventful 8-month follow-up period (20).

In the case presented in the current study, the neoplasm originated from the mucosal layer. The patient refused radical surgery, and thus ESD was performed given the large size of the mass. The treatment successfully removed the PMME mass. Notably, this is the first study to describe a case of PMME undergoing treatment with ESD by a long-term follow-up period.

In conclusion, to the best of our knowledge, this study is the first to describe the long-term efficacy of ESD for the treatment of PMME. The result of the present study revealed that ESD may be an alternative option to EMR for the treatment PMME in patients that do not present distant metastasis.

References

1. Garfinkle JM and Cahan WG: Primary melanocarcinoma of the esophagus. First histologically proved case. Cancer 5: 921-926, 1952.
2. Jiang W, Zou Z and Liu B: Primary malignant melanoma of the esophagus: A case report and review of the literature. Oncol Lett 9: 2036-2040, 2015.
3. Hamdy FC, Smith JH, Kennedy A and Thorpe JA: Long survival after excision of a primary malignant melanoma of the esophagus. Thorax 46: 397-398, 1991.
4. Zhang Y, Wang X, Xiong G, Qian Y, Wang H, Liu L, Miao L and Fan Z: Complete defect closure of gastric submucosal tumors with purse-string sutures. Surg Endosc 28: 1844-1851, 2014.
5. Kanamori N and Igaki H: A case of primary malignant melanoma of the esophagus. Jpn J Clin Oncol 38:233, 2015.
6. Eigentler TK, Caroli UM, Radny P and Garbe C: Palliative therapy of disseminated malignant melanoma: systematic review of 41 randomised clinical trials. Lancet Oncol 14: 748-759, 2003.
7. Wallis G, Sehgal V, Haider A, Bridgewater J, Novelli M, Daws K and Haidry R: Primary malignant melanoma of the esophagus. Endoscopy 47: E81-E82, 2015.
8. Sabanathan S, Eng J and Pradhan GN: Primary malignant melanoma of the esophagus. Am J Gastroenterol 84: 1475-1481, 1989.
9. Yu H, Huang XY, Li Y, Xie X, Zhou JL, Zhang LJ, Fu JH and Wang X: Primary malignant melanoma of the esophagus: A study of clinical features, pathology, management and prognosis. Dis Esophagus 24: 109-113, 2011.
10. Dennis KL, Thomas PA, Fan F and Olyaee M: Primary malignant melanoma of the esophagus: A rare entity diagnosed by endoscopic ultrasound guided fine-needle aspiration. Diagn Cytopathol 40: 462-465, 2012.

11. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, et al: Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc 66: 483-490, 2007.

12. Volpin E, Sauvanet A, Couvelard A and Belghiti J: Primary malignant melanoma of the esophagus: A case report and review of literature. Dis Esophagus 15: 244-249, 2002.

13. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al; BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-216, 2011.

14. Herman J, Duda M, Lovecek M and Svach I: Primary malignant melanoma of the esophagus treated by endoscopic ablation and interferon therapy. Dis Esophagus 14: 239-240, 2001.

15. Miyatani H, Yoshida Y, Ushimaru S, Sagihara N and Yamada S: Slow growing flat-type primary malignant melanoma of the esophagus treated with cap-assisted EMR. Dig Endosc 21: 255-257, 2009.

16. Tipirneni E, Gunaratnam NT, Tworek JA and Kodali S: Primary malignant melanoma of esophagus treated with endoscopic mucosal resection and esophagectomy. J Gastrointest Cancer 42: 266-268, 2011.

17. Kastl S, Wutke R, Czeczatka P, Hohenberger W and Horbach T: Palliation of a primary malignant melanoma of the distal esophagus by stent implantation. Report of a case. Surg Endosc 15: 1042-1043, 2001.

18. Lohmann CM, Hwu WJ, Iversen K, Jungbluth AA and Busam KJ: Primary malignant melanoma of the oesophagus: A clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens. Melanoma Res 13: 595-601, 2003.

19. Wayman J, Irving M, Russell N, Nicoll J and Raimes SA: Intraluminal radiotherapy and Nd:YAG laser photoblation for primary malignant melanoma of the esophagus. Gastrointest Endosc 59: 927-929, 2004.

20. Eleftheriadis N, Inoue H, Ikeda H, Onimaru M, Yoshida A, Hosoya T, Maselli R, Hamatani S and Kudo SE: Endoscopic submucosal dissection for primary malignant esophageal melanoma (with video). Gastrointest Endosc 78: 359-360, 2013.